| Expression pattern: |
UP |
| Associated gene: |
SOX5 |
| Associated microRNA: |
miR-588 |
| Biological function: |
promotes cisplatin chemoresistance and malignant behaviors (proliferation/survival/invasion) in DDP-resistant gastric cancer; its knockdown increases DDP sensitivity, promotes apoptosis, and suppresses tumor growth |
| Molecular mechanism: |
ceRNA mechanism: circ-LDLRAD3 sponges miR-588 to relieve repression of SOX5, thereby promoting DDP resistance and malignant phenotypes; circ-LDLRAD3 can be transferred by exosomes |
| Biological pathway or process: |
chemoresistance (promotes); proliferation (promotes); invasion (promotes); apoptosis (inhibits); ceRNA regulation (promotes) |
| Detected method: |
Q
|
| Validation methods: |
RT-qPCR; RNase R Treatment; Clinical Sample Validation; Bioinformatics Analysis; Luciferase Reporter Assay; Transfection; CCK8; Colony Formation Assay; EdU Staining; Annexin V/PI Flow Cytometry; Transwell Assay; Western Blot; IHC (Immunohistochemistry); In Vivo Animal Model |
| Clinical significance: |
circ-LDLRAD3 may serve as an exosomal biomarker to predict DDP resistance in GC; circ-LDLRAD3 high expression is associated with aggressive clinicopathologic features (e.g., TNM grade, lymph node metastasis, tumor size, histologic grade) |
| Description: |
circ-LDLRAD3 (hsa_circ_0006988) is up-regulated in cisplatin-resistant gastric cancer tissues/cells and promotes cisplatin chemoresistance, proliferation/survival and invasion. Mechanistically, it acts as a sponge for miR-588 to increase SOX5 expression, and it is enriched in exosomes from DDP-resistant GC cells. |
| Confidence score: |
0.7662 |